Vasoactive intestinal peptide induces cyclooxygenase-2 expression through nuclear factor-κB in human prostate cell lines. Differential time-dependent responses in cancer progression

Molecular and Cellular Endocrinology

Volumn 270, Issue 1-2, 2007, Pages 8-16

  Fernández Martínez, Ana B ^a   Collado, Beatriz ^a   Bajo, Ana M ^a   Sánchez Chapado, Manuel ^a,b   Prieto, Juan C ^a   Carmena, María J ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

Author keywords

COX 2; Inflammation; NF B; Prostate cancer progression; VIP

Indexed keywords

BETA ACTIN; CURCUMIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PROTEIN P50; VASOACTIVE INTESTINAL POLYPEPTIDE;

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER STAGING; CELL NUCLEUS; CYTOSOL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN ISOLATION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

CELL LINE, TUMOR; CURCUMIN; CYCLOOXYGENASE 2; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MEMBRANE PROTEINS; NF-KAPPA B; PROSTATIC NEOPLASMS; PROTEIN TRANSPORT; RNA, MESSENGER; TIME FACTORS; VASOACTIVE INTESTINAL PEPTIDE;

EID: 34247622735     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2007.01.007     Document Type: Article

References (38)

1. Aggarwal B.B., Kumar A., and Bharti A.C. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 23 (2003) 363-398
2. Aggarwal S., Ichikawa H., Takada Y., Sandur S.K., Shishodia S., and Aggarwal B.B. Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IFκB kinase and Akt activation. Mol. Pharmacol. 69 (2006) 195-206
3. Bello D., Webber M.M., Kleinman H.K., Wartinger D.D., and Rhim J.S. Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis 18 (1997) 1215-1223
4. Chang J.T., Chen I.H., Liao C.T., Wang H.M., Hsu Y.M., Hung K.F., Lin C.J., Hsieh L.L., and Cheng A.J. A reverse transcription comparative real-time PCR method for quantitative detection of angiogenic growth factors in head and neck cancer patients. Clin. Biochem. 35 (2002) 591-596
5. Charalambous M.P., Maihöfner C., Bhambra U., Lightfoot T., and Gooderham N.J. Upregulation of cyclooxigenase-2 is accompanied by increased expression of nuclear factor-κB and I κB kinase-α in human colorectal cancer epithelial cells. Br. J. Cancer 88 (2003) 1598-1604
6. Chun K.S., and Surh Y.J. Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochem. Pharmacol. 68 (2004) 1089-1100
7. Collado B., Carmena M.J., Sánchez-Chapado M., Ruíz-Villaespesa A., Bajo A.M., Fernández-Martínez A.B., Varga J.L., and Schally A.V. Expression of vasoactive intestinal peptide (VIP) and functional VIP receptors in human prostate cancer: antagonistic action of a growth-hormone-releasing hormone analog. Int. J. Oncol. 26 (2005) 1629-1635
8. Collado B., Gutiérrez-Cañas I., Rodríguez-Henche N., Prieto J.C., and Carmena M.J. Vasoactive intestinal peptide increases vascular endothelial growth factor expression and neuroendocrine differentiation in human prostate cancer LNCaP cells. Regul. Peptides 119 (2004) 69-75
9. 2+ signalling. Implications in angiogenesis and neuroendocrine differentiation. Biochim. Biophys. Acta 1744 (2005) 224-233
10. Collado B., Sánchez-Chapado M., Prieto J.C., and Carmena M.J. Hypoxia regulation of expression and angiogenic effects of vasoactive intestinal peptide (VIP) and VIP receptors in LNCaP prostate cancer cells. Mol. Cell. Endocrinol. 249 (2006) 116-122
11. Davis J., McCabe M.T., Hayward S.W., Park J.M., and Day M.L. Disruption of Rb/E2F pathway results in increased cyclooxigenase-2 expression and activity in prostate epithelial cells. Cancer Res. 65 (2005) 3633-3642
12. Delgado M., and Ganea D. Vasoactive intestinal peptide inhibits IL-8 production in human monocytes by downregulating nuclear factor κB-dependent transcriptional activity. Biochim. Biophys. Res. Commun. 302 (2003) 275-283
13. Deusth E., Maggiorella L., Eschwege P., Bourhis J., Soria J.C., and Abdulkarim B. Environmental, genetic, and molecular features of prostate cancer. Lancet Oncol. 5 (2004) 303-313
14. Di Lorenzo G., De Placido S., Autorino R., De Laurentiis M., Mignogna C., D'rmiento M., Tortora G., De Rosa G., D'rmiento M., De Sio M., Bianco A.R., and D'rmiento F.P. Expression of biomarkers modulating prostate cancer progression: implications in the treatment of the disease. Prostate Cancer Prostatic Dis. 8 (2005) 54-59
15. Foley R., Hollywood D., and Lawler M. Molecular pathology of prostate cancer: the key to identifying new biomarkers of disease. Endocr. Related Cancer 11 (2004) 477-488
16. Fradet V., Lessard L., Bégin L.R., Karakiewick P., Mes Masson A.M., and Saad F. Nuclear factor-κB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer. Clin. Cancer Res. 10 (2004) 8460-8464
17. García-Fernández M.O., Solano R.M., Carmena M.J., Busto R., Bodega G., Ruíz-Villaespesa A., and Sánchez-Chapado M. Expression of functional PACAP/VIP receptors in human prostate cancer and healthy tissue. Peptides 24 (2003) 893-902
18. Gutiérrez-Cañas I., Juarranz M.G., Collado B., Rodríguez-henche N., Chiloeches A., Prieto J.C., and Carmena M.J. Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK and PI3K. Prostate 63 (2005) 44-55
19. Gutiérrez-Cañas I., Rodríguez-Henche N., Bolaños O., Carmena M.J., Prieto J.C., and Juarranz M.G. VIP and PACAP are autocrine factors that protect the androgen-independent prostate cancer cell line PC-3 from apoptosis induced by serum withdrawal. Br. J. Pharmacol. 139 (2003) 1050-1058
20. Huang S., Pettaway C.A., Uehara H., Bucana C.D., and Fidler I.J. Blockade of NFκB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20 (2001) 4188-4197
21. Hughes-Fulford M., Li C.F., Boonyaratanakorukit J., and Sayyah S. Arachidonic acid activates phosphatidylinositol 3-kinase signalling and induces gene expression in prostate cancer. Cancer Res. 66 (2006) 1427-1433
22. Hussain T., Gupta S., and Mukhtar H. Cyclooxigenase-2 and prostate carcinogenesis. Cancer Lett. 191 (2003) 125-135
23. Jemal A., Twary R.C., Murray T., Ghafoor A., Samuels A., Ward E., Feuer E.J., and Thun M.J. Cancer statistics 2004. CA Cancer J. Clin. 54 (2004) 8-29
24. Juarranz Y., Abad C., Martínez C., Arranz A., Gutiérrez-Cañas I., Rosignoli F., Gomáriz R.P., and Leceta J. Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res. Therapy 7 (2005) R1034-R1045
25. Kirschenbaum A., Liu X.H., and Levine A.C. The role of cyclooxigenase-2 in prostate cancer. Urology 58 Suppl. 2A (2001) 127-131
26. McCarthy M.F. Targeting multiple signaling pathways as strategy for managing prostate cancer: multifocal signal modulation therapy. Integrat. Cancer Therap. 3 (2004) 349-380
27. Plonowski A., Varga J.L., Schally A.V., Krupa M., Groot K., and Halmos G. Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity. Int. J. Cancer 98 (2002) 624-629
28. Rekasi Z., Varga J.L., Schally A.V., Halmos G., Amatis P., Grooto K., and Czompoly T. Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers. Endocrinology 141 (2000) 2120-2128
29. Shigemura K., Shirakawa T., Wada Y., Kamidono S., Fujisawa M., and Gotoh A. Antitumor effects of etodolac, a selective cyclooxigenase-II inhibitor, against human prostate cancer cell lines in vitro and in vivo. Urology 66 (2005) 1239-1244
30. Shirakawa T., Hamada K., Zhang Z., Okada H., Tagawa M., Kamidono S., Kawabata M., and Gotoh A. A Cox-2 promoter-based replication-selective adenoviral vector to target the COX-2-expressing human bladder cancer cells. Clin. Cancer Res. 10 (2004) 4342-4348
31. Smith W.I., DeWitt D.L., and Garavito R.M. Cyclooxigenases: structural, cellular, and molecular biology. Ann. Rev. Biochem. 69 (2000) 145-182
32. Sternberg C.N. Highlights of contemporary issues in the medical management of prostate cancer. Crit. Rev. Oncol. Hematol. 43 (2002) 105-121
33. Vane J.R., Bakhle Y.S., and Botting R.M. Cyclooxigenases 1 and 2. Ann. Rev. Pharmacol. Toxicol. 38 (1998) 97-120
34. Vilches J., Salido M., Fernández-Segura E., and Roomans G.M. Neuropeptides, apoptosis and ion changes in prostate cancer. Methods of study and recent developments. Histol. Histopathol. 19 (2004) 951-961
35. Wagner M., Loos J., Weksler N., Gantner M., Corless C.L., Barry J.M., Beer T.M., and Gonzotto M. Resistance of prostate cancer cell lines to COX-2 inhibitor treatment. Biochem. Biophys. Res. Commun. 332 (2005) 800-807
36. Wang W., Bergh A., and Damber J.E. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxigenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate 61 (2004) 60-72
37. Zha S., Gage W.R., Sauvageot J., Saria E.A., Putzi M.J., Ewing C.M., Faith D.A., Nelson W.G., De Marzo A.M., and Isaacs W.B. Cyclooxigenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res. 61 (2001) 8617-8623
38. Zha S., Yegnasubramanian V., Nelson W.G., Isaacs W.B., and de Marzo A.M. Cyclooxigenases in cancer: progress and perspective. Cancer Lett. 215 (2004) 1-20